Fairfield, Bush & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Fairfield, Bush & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33	Closed	-$3.39K	–	560
2023 Q2	$3.39K	Buy	+33	New	+$3.48K	﹤0.01%	390
2022 Q3	–	Sell	-33	Closed	-$3K	–	513
2022 Q2	$3K	Buy	+33	New	+$3.13K	﹤0.01%	385

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fairfield, Bush & Co's HZNP Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 33 shares — an estimated $3.39K sold.

Fairfield, Bush & Co first reported a position in HZNP in Q2 2022 and held it in 2 quarters. The position peaked at $3.39K in Q2 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Fairfield, Bush & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Fairfield, Bush & Co sold 33 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $3.39K.
Fairfield, Bush & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 2 quarters.
Fairfield, Bush & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.39K in Q2 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.